Subsequent to evaluating the topline interim analysis, which did not achieve its primary or secondary endpoints, the Company has discontinued the Phase 2 study of ABP-450 for the prevention of chronic migraine, which had previously completed enrollment and dosing of patients, and ceased enrollment and dosing of patients in the Company’s migraine open label extension study. Patients in both studies will be monitored for safety purposes through the 12-week period following their last treatment. The Company will continue its analysis of interim data from the study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AEON:
- AEON Biopharma Halts Migraine Study and Evaluates Strategy
- Aeon Biopharma price target lowered to $6 from $18 at H.C. Wainwright
- Aeon Biopharma provides update on development pipeline
- Aeon’s results from Phase 2 trial of ABP-450 didn’t meet primary endpoint
- AEON Biopharma Phase 2 Migraine Treatment Trial Results